These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Therapeutic use of fresh plasma and "virus-safe" plasma]. Seyfert UT; Lorenz C; Espig J; Heinrich H; Grund S; Rupp KH; Wenzel E Beitr Infusionsther; 1991; 28():35-48. PubMed ID: 1725654 [TBL] [Abstract][Full Text] [Related]
4. A probabilistic model for analyzing viral risks of plasma-derived medicinal products. Janssen MP; Over J; van der Poel CL; Cuijpers HT; van Hout BA Transfusion; 2008 Jan; 48(1):153-62. PubMed ID: 17894786 [TBL] [Abstract][Full Text] [Related]
6. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Klein HG; Glynn SA; Ness PM; Blajchman MA; Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769 [TBL] [Abstract][Full Text] [Related]
7. Skin disinfection and bacterial contamination of blood components: be simple. Bueno JL Transfusion; 2010 Jan; 50(1):5-8. PubMed ID: 20233345 [No Abstract] [Full Text] [Related]
8. [Therapy with blood and blood products]. Kreienbühl G Urologe A; 1996 Jan; 35(1):69-85. PubMed ID: 8851853 [No Abstract] [Full Text] [Related]
9. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902 [TBL] [Abstract][Full Text] [Related]
10. Update on pathogen reduction technology for therapeutic plasma: an overview. Solheim BG; Seghatchian J Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528 [TBL] [Abstract][Full Text] [Related]
11. Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives. Berting A; Goerner W; Spruth M; Kistner O; Kreil TR J Med Virol; 2005 Apr; 75(4):603-7. PubMed ID: 15714487 [TBL] [Abstract][Full Text] [Related]
12. Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages. Vox Sang; 1988; 54(4):228-45. PubMed ID: 3388821 [No Abstract] [Full Text] [Related]
13. Viral infectivity of albumin and plasma protein fraction. Erstad BL Pharmacotherapy; 1996; 16(6):996-1001. PubMed ID: 8947970 [TBL] [Abstract][Full Text] [Related]
14. Risk of virus transmission by tissue, blood, and plasma products. Lelie PN; Zaaijer HL; Cuypers HT Transplant Proc; 1996 Oct; 28(5):2939. PubMed ID: 8908132 [No Abstract] [Full Text] [Related]
15. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007;92:846-9. Gröner A Haematologica; 2008 Feb; 93(2):e24-6; author reply e27. PubMed ID: 18245642 [No Abstract] [Full Text] [Related]
16. Are inactivation procedures for blood products good or bad? Caspari G BMJ; 2002 Nov; 325(7372):1116. PubMed ID: 12424183 [No Abstract] [Full Text] [Related]
17. Beyond HIV, HBV and HCV--how to deal with other viruses? Minor PD Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138 [TBL] [Abstract][Full Text] [Related]
18. Transfusion-transmitted infection in hemophilia in developing countries. Yee TT; Lee CA Semin Thromb Hemost; 2005 Nov; 31(5):527-37. PubMed ID: 16276461 [TBL] [Abstract][Full Text] [Related]
19. Viral contamination of blood products. Thomas DP Lancet; 1994 Jun; 343(8913):1583-4. PubMed ID: 7911913 [No Abstract] [Full Text] [Related]
20. Bacterial contamination of cellular blood components: risks, sources and control. Blajchman MA Vox Sang; 2004 Jul; 87 Suppl1():98-103. PubMed ID: 15200616 [No Abstract] [Full Text] [Related] [Next] [New Search]